Clinical trial
Phase III Study of BAY43-9006 in Patients With Advanced Hepatocellular Carcinoma…
NCT00494299 · Bayer, Industry · Completed
Key facts
| NCT number | NCT00494299 |
|---|---|
| Title | Phase III Study of BAY43-9006 in Patients With Advanced Hepatocellular Carcinoma (HCC) Treated After Transcatheter Arterial Chemoembolization (TACE) |
| Official title | Phase III Study of BAY43-9006 in Patients With Advanced Hepatocellular Carcinoma (HCC) Treated After Transcatheter Arterial Chemoembolization (TACE) |
| Lead sponsor | Bayer, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Carcinoma, Hepatocellular |
| Intervention type | Drug |
| Interventions | Sorafenib (Nexavar, BAY43-9006), Placebo |
| Enrollment | 458 |
| Start date | Apr 1, 2006 |
| Primary completion | Jul 1, 2009 |
| Completion | Nov 1, 2010 |
| First posted | Jun 29, 2007 |
| Last update posted | Dec 20, 2013 |
| Countries | Japan, South Korea |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: